Previous 10 | Next 10 |
SAN DIEGO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present clinical and preclinica...
Summary This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total retu...
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, t...
Summary Fate Therapeutics has potential inflection points stemming from clinical trial and regulatory momentum in the next 6-12 months. For those taking speculative positions within healthcare, this could present with potential upsides post-event(s). Those investors looking fo...
The shares of clinical-stage biotech Fate Therapeutics ( NASDAQ: FATE ) inched higher in the pre-market trading Thursday after Wells Fargo resumed its coverage with an Overweight recommendation citing two key upcoming catalysts scheduled for Q4 2022. The analysts James Shin ...
Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...
Cathie Wood is the all-star stock picker in charge of the funds at ARK Invest, and she's a favorite among fans of high-growth stocks. Wood divides her funds into specific market verticals like disruptive innovation, space exploration, next-generation internet, and cryptocurrency. She's ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ra2 studio/Shutterstock Shares of Fate Therapeutics (NASDAQ: FATE ) stock are up 3% following a massive purchase by two of Cathie Wood’s exchange-traded funds (ETFs). Fate is a clinical stage biotec...
TCR - CAR + iPSC-derived CD8αβ T Cells Induced Complete and Durable Responses In Vivo in Systemic Leukemia Model Cell-surface Markers, Gene Transcription Profile, and In Vivo Anti-tumor Activity of TCR - CAR + iPSC-de...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-term growth potential. Ho...
News, Short Squeeze, Breakout and More Instantly...
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
2024-06-17 07:30:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for FATE on June 17, 2024 06:03AM ET. The previous analyst recommendation was Neutral. FATE was trading at $3.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellula...